Search in:

Advanced search

Baylor University Medical Center Proceedings

The peer-reviewed journal of Baylor Scott & White Health

Volume 18, 2005 - Issue 4

Submit an article Journal homepage

Free access

189

Views

CrossRef citations to date

Altmetric

Articles

Renal Cell Carcinoma: Diagnosis and Treatment, 1994–2003

Thomas E. HutsonCorrespondence[email protected]

, DO, PharmD

Pages 337-340 | Published online: 11 Dec 2017

Cite this article
https://doi.org/10.1080/08998280.2005.11928093

References
Citations
Metrics
Reprints & Permissions
View PDF PDF

Linehan WM, Zbar B, Bates SE, Zelefsky MJ, Yang JC. Cancer of the kidney and ureter. In DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2001: 1362–1396.
Google Scholar
Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non–clear-cell histology. J Clin Oncol 2002;20: 2376–2381.
PubMed Web of Science ®Google Scholar
Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005;55: 10–30.
PubMed Web of Science ®Google Scholar
U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999 Incidence. Atlanta, GA: Centers for Disease Control and Prevention, 2002: 1–292.
Google Scholar
Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000;163: 408–417.
PubMed Web of Science ®Google Scholar
Motzer RJ, Bander NH, Nanus DM. Renal cell carcinoma. N Engl J Med 1996;335: 865–875.
PubMed Web of Science ®Google Scholar
Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA 1999;281: 1628–1631.
PubMed Web of Science ®Google Scholar
Tsui KH, Shvarts O, Smith RB, Figlin R, de Kernion JB, Belldegrun A. Renal cell carcinoma: prognostic significance of incidentally detected tumors. J Urol 2000;163: 426–430.
PubMed Web of Science ®Google Scholar
Staehler G, Brkovic D. The role of radical surgery for renal cell carcinoma with extension into the vena cava. J Urol 2000;163: 1671–1675.
PubMed Web of Science ®Google Scholar
Van Poppel H, Bamelis B, Oyen R, Baert L. Partial nephrectomy for renal cell carcinoma can achieve long-term tumor control. J Urol 1998;160 (3 Pt 1): 674–678.
Web of Science ®Google Scholar
Flanigan RC, Blumenstein BA, Salmon S, Crawford E. Cytoreduction nephrectomy in metastatic renal cancer: The results of Southwest Oncology Group Trial 8949 [abstract]. Proc Ann Mtg Am Soc Clin Oncol 2000;19: 2a.
Google Scholar
Storkel S, Eble JN, Adlakha K, Amin M, Blute ML, Bostwick DG, Darson M, Delahunt B, Iczkowski K. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997;80: 987–989.
PubMed Web of Science ®Google Scholar
Delahunt B, Velickovic M, Grebe SK. Evolving classification of renal cell neoplasia. Expert Rev Anticancer Ther 2001;1: 576–584.
PubMedGoogle Scholar
Leroy X, Zini L, Leteurtre E, Zerimech F, Porchet N, Aubert JP, Gosselin B, Copin MC. Morphologic subtyping of papillary renal cell carcinoma: correlation with prognosis and differential expression of MUC1 between the two subtypes. Mod Pathol 2002;15: 1126–1130.
PubMed Web of Science ®Google Scholar
Onishi T, Oishi Y, Yanada S, Abe K, Hasegawa T, Maeda S. Prognostic implications of histological features in patients with chromophobe cell renal carcinoma. BJU Int 2002;90: 529–532.
PubMed Web of Science ®Google Scholar
Said JW, Thomas G, Zisman A. Kidney pathology: current classification of renal cell carcinoma. Curr Urol Rep 2002;3: 25–30.
Google Scholar
Guinan P, Sobin LH, Algaba F, Badellino F, Kameyama S, MacLennan G, Novick A. TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997;80: 992–993.
PubMed Web of Science ®Google Scholar
Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6: 655–663.
PubMed Web of Science ®Google Scholar
Fiori E, De Cesare A, Galati G, Bononi M, D'Andrea N, Barbarosos A, Izzo L, Bolognese A. Prognostic significance of primary-tumor extension, stage and grade of nuclear differentiation in patients with renal cell carcinoma. J Exp Clin Cancer Res 2002;21: 229–232.
Web of Science ®Google Scholar
Saidi JA, Newhouse JH, Sawczuk IS. Radiologic follow-up of patients with T1–3a,b,c or T4N+M0 renal cell carcinoma after radical nephrectomy. Urology 1998;52: 1000–1003.
Web of Science ®Google Scholar
Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345: 1655–1659.
PubMed Web of Science ®Google Scholar
Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Lancet 1999;353: 14–17.
Google Scholar
Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 1997;80: 1198–1220.
PubMed Web of Science ®Google Scholar
Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T; Groupe Francais d'Immunotherapie. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998;338: 1272–1278.
PubMed Web of Science ®Google Scholar
Ritchie AWS, Griffiths G, Cook P, Oliver RT, Hancock B, Parmer MK. Alpha interferon improves survival in patients with metastatic renal carcinoma—preliminary results of an MRC randomized controlled trial [abstract]. Proc Ann Mtg Am Soc Clin Oncol 1998;17: 31.
Google Scholar
Bower M, Roylance R, Waxman J. Immunotherapy for renal cell cancer. QJM 1998;91: 597–602.
Google Scholar
Boccardo F, Rubagotti A, Canobbio L, Galligioni E, Sorio R, Lucenti A, Cognetti F, Ruggeri E, Landonio G, Baiocchi C, Besana C, Citterio G, De Rosa M, Calabresi F. Interleukin-2, interferon-alpha and interleukin-2 plus interferon-alpha in renal cell carcinoma. A randomized phase II trial. Tumori 1998;84: 534–539.
Web of Science ®Google Scholar
De Mulder PH, Oosterhof G, Bouffioux C, van Oosterom AT, Vermeylen K, Sylvester R; The EORTC Genitourinary Group. EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. Br J Cancer 1995;71: 371–375.
Web of Science ®Google Scholar
Fossa SD, Martinelli G, Otto U, Schneider G, Wander H, Oberling F, Bauer HW, Achtnicht U, Holdener EE. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study. Ann Oncol 1992;3: 301–305.
PubMed Web of Science ®Google Scholar
Kirkwood JM, Harris JE, Vera R, Sandler S, Fischer DS, Khandekar J, Ernstoff MS, Gordon L, Lutes R, Bonomi P, et al. A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res 1985;45: 863–871.
PubMed Web of Science ®Google Scholar
Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, Loehrer P, Wilding G, Fairclough DL, Cella D, Mazumdar M. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000;18: 2972–2980.
PubMed Web of Science ®Google Scholar
Muss HB, Costanzi JJ, Leavitt R, Williams RD, Kempf RA, Pollard R, Ozer H, Zekan PJ, Grunberg SM, Mitchell MS, et al. Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration. J Clin Oncol 1987;5: 286–291.
PubMed Web of Science ®Google Scholar
Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13: 688–696.
PubMed Web of Science ®Google Scholar
Zisman A, Pantuck AJ, Chao D, Dorey F, Said JW, Gitlitz BJ, de Kernion JB, Figlin RA, Belldegrun AS. Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm better correlates with clinical outcome. J Urol 2001;166: 54–58.
PubMed Web of Science ®Google Scholar
Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz EM. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 2000;18: 1928–1935.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Renal Cell Carcinoma: Diagnosis and Treatment, 1994–2003

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Renal Cell Carcinoma: Diagnosis and Treatment, 1994–2003

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date